All In Biotech

Drug Trial Radar · NCT07818499

A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma

A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of BL-M08D1 for Injection in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

204

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Sponsor type
Industry
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
First posted
Sep 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase Ib/II study is a clinical trial to explore the efficacy and safety of BL-M08D1 for injection in combination with immunochemotherapy in patients with diffuse large B-cell lymphoma.

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

  • BL-M08D1Drug

    Administration by intravenous infusion for a cycle of 3 weeks.

  • RituximabDrug

    Administration by intravenous infusion for a cycle of 3 weeks.

  • Gemcitabine HydrochlorideDrug

    Administration by intravenous infusion for a cycle of 3 weeks.

  • OxaliplatinDrug

    Administration by intravenous infusion for a cycle of 3 weeks.

  • CyclophosphamideDrug

    Administration by intravenous infusion for a cycle of 3 weeks.

  • Doxorubicin Hydrochloride LiposomeDrug

    Administration by intravenous infusion for a cycle of 3 weeks.

  • Vincristine SulfateDrug

    Administration by intravenous infusion for a cycle of 3 weeks.

  • Prednisone Acetate TabletsDrug

    Oral administration for a cycle of 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase II Dose (RP2D)Time frame: Up to approximately 24 months
  2. Objective Response Rate (ORR)Time frame: Up to approximately 24 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.